APLMW

Apollomics (APLMW)

Apollomics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:APLMW

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/04	21 : 00	GlobeNewswire Inc.	Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:APLMW	Apollomics Inc
2024/05/31	05 : 15	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:APLMW	Apollomics Inc
2024/05/30	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:APLMW	Apollomics Inc
2024/05/30	06 : 12	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:APLMW	Apollomics Inc
2024/05/29	21 : 00	GlobeNewswire Inc.	Apollomics Announces Presentation at the 2024 BIO International Convention	NASDAQ:APLMW	Apollomics Inc
2024/05/25	06 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:APLMW	Apollomics Inc
2024/05/25	05 : 58	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:APLMW	Apollomics Inc
2024/05/21	05 : 32	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:APLMW	Apollomics Inc
2024/05/21	05 : 15	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:APLMW	Apollomics Inc
2024/05/21	05 : 15	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:APLMW	Apollomics Inc
2024/05/09	05 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:APLMW	Apollomics Inc
2024/05/09	05 : 05	GlobeNewswire Inc.	Apollomics Announces Private Placement Financing and Addition to Board of Directors	NASDAQ:APLMW	Apollomics Inc
2024/04/25	21 : 30	GlobeNewswire Inc.	Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene	NASDAQ:APLMW	Apollomics Inc
2024/04/10	20 : 00	GlobeNewswire Inc.	Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	NASDAQ:APLMW	Apollomics Inc
2024/04/02	21 : 00	GlobeNewswire Inc.	Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting	NASDAQ:APLMW	Apollomics Inc
2024/03/28	20 : 00	GlobeNewswire Inc.	Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results	NASDAQ:APLMW	Apollomics Inc
2024/03/26	21 : 00	GlobeNewswire Inc.	Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024	NASDAQ:APLMW	Apollomics Inc
2024/03/04	21 : 00	GlobeNewswire Inc.	Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer	NASDAQ:APLMW	Apollomics Inc
2024/02/07	21 : 00	GlobeNewswire Inc.	Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:APLMW	Apollomics Inc
2024/01/20	06 : 15	GlobeNewswire Inc.	Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	NASDAQ:APLMW	Apollomics Inc
2024/01/18	06 : 30	GlobeNewswire Inc.	Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference	NASDAQ:APLMW	Apollomics Inc
2024/01/03	21 : 00	GlobeNewswire Inc.	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	NASDAQ:APLMW	Apollomics Inc
2024/01/03	06 : 30	GlobeNewswire Inc.	Apollomics to Present at the 2024 Biotech Showcase	NASDAQ:APLMW	Apollomics Inc
2023/12/04	21 : 00	GlobeNewswire Inc.	Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation	NASDAQ:APLMW	Apollomics Inc
2023/11/29	21 : 30	GlobeNewswire Inc.	Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	NASDAQ:APLMW	Apollomics Inc
2023/11/28	21 : 00	GlobeNewswire Inc.	Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)	NASDAQ:APLMW	Apollomics Inc
2023/11/16	22 : 30	GlobeNewswire Inc.	Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer	NASDAQ:APLMW	Apollomics Inc
2023/10/31	21 : 30	GlobeNewswire Inc.	Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation	NASDAQ:APLMW	Apollomics Inc
2023/10/26	21 : 50	GlobeNewswire Inc.	Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion	NASDAQ:APLMW	Apollomics Inc
2023/10/23	21 : 30	GlobeNewswire Inc.	Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%	NASDAQ:APLMW	Apollomics Inc